11 Best Pharma and Biotech Stocks to Buy According to Jim Simons' Euclidean Capital
In this article, we will discuss the 11 best pharma and biotech stocks to buy according to Jim Simons' Euclidean Capital.
Rubius Therapeutics Inc. (RUBY)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 0 | $0 | 0% | |
| 2. | Citadel Investment Group Ken Griffin | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% | ||
| 4. | Renaissance Technologies Jim Simons | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.44 | 30,000 | Director | 4,720,012 | 2022-04-21 | Filing | |
| $29.00 | 70,000 | Large Shareholder | 2,633,703 | 2021-03-19 | Filing | |
| $29.00 | 70,000 | Large Shareholder | 5,859,414 | 2021-03-19 | Filing | |
| $29.00 | 70,000 | Large Shareholder | 15,393,593 | 2021-03-19 | Filing | |
| $5.52 | 19,000 | Officer | 19,000 | 2020-04-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.13 | 10,385 | Officer | 0 | 2023-02-24 | Filing | |
| $0.25 | 8,448 | Director | 66,082 | 2023-02-01 | Filing | |
| $0.25 | 3,878 | Officer | 10,385 | 2023-02-01 | Filing | |
| $0.24 | 7,240 | Director | 74,530 | 2023-01-31 | Filing | |
| $0.24 | 2,593 | Officer | 18,391 | 2023-01-31 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% |
News See All
Is Rubius (RUBY) A Good Stock To Buy Now?
After several tireless days we have finished crunching the numbers from nearly 817 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed...
Hedge Funds Are Selling Rubius Therapeutics, Inc. (RUBY)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Hedge Fund and Insider Trading News: Starboard Value L.P., Horseman Capital Management, Amber Capital, Elliott Management, Silvercrest Asset Management Group Inc (SAMG), Okta Inc (OKTA), and More
Future rises in the cost of natural gas following the recent oil price crash may squeeze utility companies’ profits, with US names potentially proving a lucrative short bet for hedge funds.
Rubius Therapeutics, Inc. (RUBY): Are Hedge Funds Right About This Stock?
We at Insider Monkey have gone over 752 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of September...
Should You Buy Rubius Therapeutics, Inc. (RUBY)?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities...
Hedge Fund and Insider Trading News: Third Point, Mike Novogratz, Know Labs Inc (KNWN), Novartis AG (NVS), and More
ZURICH (Reuters) - Nestle (NESN.S) Chief Executive Mark Schneider said he was convinced the food giant had the right strategy in place to further improve sales and profitability as it seeks to head off...